MacMillan J F, Crow T J, Johnson A L, Johnstone E C
Br J Psychiatry. 1986 Feb;148:128-33. doi: 10.1192/bjp.148.2.128.
Of 253 patients from nine medical centres identified with first episodes of schizophrenic illness, 17 did not achieve discharge during the period of trial recruitment. 120 entered a randomised controlled trial of neuroleptic medication and were followed-up, as were 116 who were eligible for the trial but did not enter it. Overall, 60% of the sample had relapsed within two years of discharge; age, sex, ethnic origin, duration of admission, social withdrawal before admission, and type of onset of illness were not significantly related to relapse. Relapse rates were lower on active trial or standard medication than placebo, but however assessed, outcome at this early stage was poor for many patients.
在来自9个医疗中心的253例首次诊断为精神分裂症的患者中，有17例在试验招募期间未出院。120例进入了抗精神病药物的随机对照试验并接受随访，另外116例符合试验条件但未参加。总体而言，60%的样本在出院后两年内复发；年龄、性别、种族、住院时间、入院前社交退缩情况以及疾病发作类型与复发无显著相关性。接受活性试验药物或标准药物治疗的复发率低于接受安慰剂治疗的，但无论如何评估，许多患者在这一早期阶段的预后都很差。
